Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non–Small Cell Lung Cancer Harboring Mesenchymal–Epithelial Transition Exon 14 Skipping

OBJECTIVES: From the US Medicare perspective, this study compared the cost-effectiveness of tepotinib and capmatinib for treating metastatic non–small cell lung cancer with tumors harboring mesenchymal–epithelial transition factor gene exon 14 skipping. METHODS: A 3-state partitioned survival model...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Mo, Vioix, Helene, Sachdev, Rameet, Stargardter, Matthew, Tosh, Jon, Pfeiffer, Boris M., Paik, Paul K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424058/
https://www.ncbi.nlm.nih.gov/pubmed/36503033
http://dx.doi.org/10.1016/j.jval.2022.11.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424058/
https://www.ncbi.nlm.nih.gov/pubmed/36503033
http://dx.doi.org/10.1016/j.jval.2022.11.018

Ejemplares similares